Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dupilumab

dupilumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dupilumab

50 trials tracked of dupilumab: 32 in phase 3 or 4 and 25 with published results. The most-cited published study has 2081 citations.

50Trials tracked
32Phase 3 & 4
0Recruiting
25With published results
Phase distribution
Phase 4 9 Phase 3 23 Phase 2 18
  1. Phase 3 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed · 2,081 cited
  2. Phase 3 Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed · 2,078 cited
  3. Phase 3 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) Completed · 1,987 cited
  4. Phase 3 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma Completed · 1,186 cited
  5. Phase 3 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 497 cited
  6. Phase 3 Open-label Study of Dupilumab in Patients With Atopic Dermatitis Completed · 237 cited
Show 44 more trials
  1. Phase 3 A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) Completed · 213 cited
  2. Phase 3 Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) Completed · 125 cited
  3. Phase 3 Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed · 124 cited
  4. Phase 4 The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma Completed · 80 cited
  5. Phase 3 Evaluation of Dupilumab in Children With Uncontrolled Asthma Completed · 60 cited
  6. Phase 3 A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable Completed · 57 cited
  7. Phase 4 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Completed · 42 cited
  8. Phase 3 Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Completed · 40 cited
  9. Phase 3 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Completed · 38 cited
  10. Phase 3 Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) Completed · 27 cited
  11. Phase 3 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Completed · 26 cited
  12. Phase 3 Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis Completed · 26 cited
  13. Phase 3 Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) Completed · 14 cited
  14. Phase 3 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Completed · 4 cited
  15. Phase 4 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Completed · 3 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) Completed · 3 cited
  17. Phase 3 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 2 cited
  18. Phase 3 Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Completed · 2 cited
  19. Phase 4 The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Completed
  20. Phase 4 SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" Completed
  21. Phase 4 A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma Completed
  22. Phase 4 Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma Completed
  23. Phase 4 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Completed
  24. Phase 4 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Completed
  25. Phase 3 Dupilumab in Chinese Adult Participants With CRSwNP Completed
  26. Phase 3 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) Completed
  27. Phase 2 Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants Completed
  28. Phase 2 Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Completed
  29. Phase 2 A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) Completed
  30. Phase 2 Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy Completed
  31. Phase 2 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Completed
  32. Phase 2 An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma Completed
  33. Phase 2 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) Completed
  34. Phase 2 Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Completed
  35. Phase 2 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Completed
  36. Phase 2 An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis Completed
  37. Phase 2 Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients Completed
  38. Phase 2 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed
  39. Phase 2 Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) Completed
  40. Phase 2 Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed
  41. Phase 2 Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) Completed
  42. Phase 2 Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) Completed
  43. Phase 2 Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Completed
  44. Phase 2 Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polyps
Allergy & Immunology Sys. Review
Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polyps Biologics May Help Chronic Sinusitis With Nasal Polyps
This narrative review examines the efficacy of biologics, including dupilumab, mepolizumab, omalizumab, and tezepelumab, for patients with c…
A new review suggests biologic drugs may improve sinus symptoms, smell, and asthma in people with nasal polyps.
Frontiers Sep 11, 2026
Depemokimab shows no significant difference from other biologics in reducing severe asthma exacerbations
Allergy & Immunology Sys. Review
Depemokimab shows no significant difference from other biologics in reducing severe asthma exacerbations Depemokimab Shows Similar Results to Other Biologics for Severe Asthma
This systematic review and indirect treatment comparison evaluated depemokimab against omalizumab, benralizumab, dupilumab, and placebo in p…
A new review finds that the drug depemokimab performs similarly to other established biologics in reducing severe asthma flare-ups.
Sep 2, 2026
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis
Allergy & Immunology Sys. Review
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis New data shows different treatments for eosinophilic esophagitis symptoms
This network meta-analysis evaluates various treatments for eosinophilic esophagitis in adolescents and adults. The analysis indicates that …
New research identifies specific medications that help improve swallowing difficulties for adults and teens with eosinophilic esophagitis.
Sep 1, 2026
Microbial dysbiosis drives recurrence in type 2 chronic rhinosinusitis with nasal polyps
Orthopedics & Sports Medicine Sys. Review
Microbial dysbiosis drives recurrence in type 2 chronic rhinosinusitis with nasal polyps Microbiome Research Offers New Insights into Chronic Sinusitis Treatment
This scoping review examines the role of the sinus microbiome and targeted interventions, including dupilumab, in type 2 chronic rhinosinusi…
New research highlights how specific bacteria in the nose may drive recurring symptoms in patients with chronic rhinosinusitis and nasal pol…
Frontiers Aug 4, 2026
Type-2 targeted biologics reduce moderate-to-severe exacerbations in patients with eosinophilic or type 2 COPD
Pulmonology & Critical Care Meta-analysis
Type-2 targeted biologics reduce moderate-to-severe exacerbations in patients with eosinophilic or type 2 COPD New data shows how specific drugs reduce COPD flare ups
This systematic review and meta-analysis of placebo-controlled trials evaluates dupilumab, mepolizumab, and benralizumab for moderate-to-sev…
Specific targeted treatments show promise in reducing severe flare-ups for people with certain types of chronic lung disease.
Jul 6, 2026
Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
Dermatology RCT
Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis Long-term dupilumab use shows low infection rates in skin conditions
A five-year open-label extension study confirms that dupilumab maintains a favorable safety profile regarding infection rates in adult patie…
A five-year study of adults with moderate to severe atopic dermatitis suggests that long-term dupilumab treatment is not linked to increased…
Jul 1, 2026
Dupilumab as an off-label adjunctive approach facilitates corticosteroid minimization in severe pemphigus vulgaris
Rheumatology Guideline
Dupilumab as an off-label adjunctive approach facilitates corticosteroid minimization in severe pemphigus vulgaris New approach helps manage severe skin disease with fewer steroids
This case report describes the use of dupilumab as an off-label adjunctive corticosteroid-minimizing approach for a patient with severe muco…
A new way to treat a severe blistering skin disease may help patients who cannot safely take high doses of steroids.
Frontiers Jun 28, 2026
Biologic-assisted immunotherapy including omalizumab and dupilumab may support oral and sublingual immunotherapy for pediatric food allergies
Allergy & Immunology Meta-analysis
Biologic-assisted immunotherapy including omalizumab and dupilumab may support oral and sublingual immunotherapy for pediatric food allergies New review explores biologic drugs for food allergy in children
This systematic review examines the efficacy, safety, and clinical applicability of biologic-assisted immunotherapies, such as omalizumab an…
A systematic review looks at whether adding biologic drugs like omalizumab to immunotherapy helps kids with food allergies.
Frontiers Jun 22, 2026
Review reframes COPD therapy toward integrated death program modulation by inflammatory endotype
Allergy & Immunology Sys. Review
Review reframes COPD therapy toward integrated death program modulation by inflammatory endotype New research links cell death types to COPD inflammatory patterns
This review synthesizes mechanistic associations between cell death pathways and COPD inflammatory endotypes. The authors describe preferent…
This review suggests specific cell death pathways may help explain how different COPD types respond to treatments like dupilumab.
Frontiers May 13, 2026
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles
Pulmonology & Critical Care Meta-analysis
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles New drugs cut COPD flare-ups for patients with high eosinophils
This living evidence synthesis evaluates dupilumab and mepolizumab in 7,359 COPD patients. Results indicate reduced annual exacerbation rate…
New biologic drugs lower the yearly number of COPD flare-ups for patients with high eosinophil counts while keeping side effects low
May 3, 2026
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026

All dupilumab Articles